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ABSTRACT  Background - Alpha-1-antitrypsin deficiency is a genetic disorder which is transmitted in a co-dominant,
autosomal form. Alpha-1-antitrypsin deficiency affects mainly the lungs and the liver leading, in the latter case, to neonatal
cholestasis, chronic hepatitis or cirrhosis. A precise diagnosis of Alpha-1-antitrypsin deficiency may be obtained by
biochemical or molecular analysis. Objective - The purpose of this study was to use DNA analysis to examine the presence
of an alpha-1-antitrypsin deficiency in 12 children suspected of having this deficiency and who showed laboratory and
clinical characteristics of the disease. Patients and Methods - Twelve patients, aged 3 months to 19 years, who had serum
alpha-1-antitrypsin levels lower than normal and/or had hepatic disease of undefined etiology were studied. The mutant
alleles S and Z of the alpha-1-antitrypsin gene were investigated in the 12 children. Alpha-1-antitrypsin gene organization
was analyzed by amplification of genoma through the polymerase chain reaction and digestion with the restriction enzymes
Xmnl (S allele) and Taq 1 (Z allele). Results - Seven of the 12 patients had chronic liver disease of undefined etiology and
the other five patients had low serum levels of alpha-1-antitrypsin as well as a diagnosis of neonatal cholestasis and/or
chronic liver disease of undefined etiology. Five of the 12 patients were homozygous for the Z allele (ZZ) and two had the
S allele with another allele (*S) different from Z. Conclusion - These results show that alpha-1-antitrypsin deficiency is
relatively frequent in children with chronic hepatic disease of undefined etiology and/or low alpha-1-antitrypsin levels
(41.6%). A correct diagnosis is important for effective clinical follow-up and for genetic counseling.
HEADINGS  Alpha-1-antitrypsin deficiency. Molecular diagnosis. Liver biopsy.
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INTRODUCTION
Alpha-1-antitrypsin (A1AT) is a 52 kDa glycoprotein produced
mainly by hepatocytes which release 2 g of this protein, per day, into
the blood stream(36). The main function of A1AT is to inhibit the
action of neutrophilic elastase, a serine protease that hydrolyzes
elastin fibers in the lungs(38). Mutations in the gene encoding for A1AT
produce a protein with no inhibitory capacity and may lead to the
accumulation of A1AT in inclusion corpuscles in hepatocytes, thereby
a reducing the normal serum levels of this protein(4). This deficiency
is reflected as lung emphysema, chronic bronchitis or bronchiectasis(9).
The accumulation of mutant A1AT in hepatocytes may also lead to
neonatal cholestasis, chronic hepatopathy or cirrhosis(33, 34).
The A1AT gene is highly polymorphic, co-dominant and is located
on the longer arm of chromosome 14 (14q 31-32.3)(20, 29). Seventyfive
alleles (designated A-Z acording to their isoeletric points) have been
described for this gene based on isoelectric focusing of serum between
pH 4 (anode) and pH 5 (cathode) in polyacrylamide gels. The common
variants migrate to the center of the gel and therefore belong to the M
(middle) family. A deficient variant, originally described by LAURELL
and ERIKSSON in 1963(21), migrates towards the cathode and is
denominated Z. Another variant, which moves slowly in the gel, is
denominated S(5). This polymorphic locus is generally know as the
Pi (protease inhibitor) system. Most of the variants produce A1AT of
normal quantity and quality(7, 8, 25). However, some alleles such as variants
S and Z are associated with a deficient condition that attains
polymorphic frequencies as Caucasian populations and cases of a null
allele in which protein production is totally absent have been reported(10).
The S allele results from the substitution of adenine by thiamin in
exon III of the gene, which leads to glutamic acid at position 264 being
exchanged for valine and the consequent formation of an unstable protein
structure(10, 11, 19). The Z allele results from the substitution of guanine at
position 342 by adenine in exon V of the gene and leads to the formation
of a protein that collects on the inner rough surface of the hepatocyte
endoplasmic reticulum(6). The diagnosis of a deficient condition is usually
made after quantification of the serum levels of the protein together with
electrophoretic profile after isoelectric focusing(23, 37). A more precise
diagnosis requires gene analysis using DNA based techniques(12, 14, 26).
The objective of this study was to identify S and Z allele carriers
in patients suspected of having this deficiency and who showed
laboratory and clinical characteristics of this disease.
PATIENTS AND METHODS
Patients
During the period from February, 1988 to August, 1997, a great
number of patients were referred to the Pediatric Gastroenterological
Service, State University of Campinas, Campinas, SP, Brazil, in order
to investigate hepatic diseases. From this number only 12 patients
did not show any definite diagnosis (negative results to viral hepatitis,
autoimmune hepatitis and Wilsons disease). Those patients were
undergone to a molecular analysis of A1AT.
Methods
1  Study Protocol
A protocol was filled in with data on the levels of the following
parameters: 1). serum level of A1AT determined by radial
immunodiffusion (normal values of 1.9-3.5 g/L) or nephelometry
(Array® 360 System, Beckman Instruments, Inc., USA - normal
level of 0.83-1.99 g/L); 2). alanine aminotransferase (ALT, normal
serum levels up to 40 U/L); 3). alkaline phosphate (AP, normal
serum levels up to 645 U/L), and 4). gammaglutamyl transpeptidase
(γGT, normal levels of up to 50 U/L for males and 32 U/L for
females).
2 - Liver Biopsy
Percutaneous liver biopsies were obtained as described by
MOWAT(24) using local anesthesia in patients fasted for at least 4 h,
with venoclysis and normal prothrombin activity. The fragment
obtained was immediately placed in 10% formalin and then processed
and stained with hematoxylin-eosin, Massons trichromic, Prussian
blue and silver impregnation of the reticulum fibers. Special staining
was obtained using PAS (periodic acid-Schiff) followed by treatment
with diastase. The persistence of eosinophil-appearing cytoplasmic
granules even after use of diastase was considered positive for A1AT
deficiency.
3 - Molecular analysis
In order to investigate the mutant alleles S and Z of the A1AT, it
was done a DNA extraction of peripheral blood leukocytes as used in
the method described by WOODHEAD et al.(39).
DNA analysis was done using a modified method of amplification
involving the polymerase chain reaction (PCR) which creates
restriction sites for the enzymes XmnI (S allele) and Taq I (Z allele)(2,
30). The primers used for the S allele were p7553 (5-CGTTTAGG-
CATGAATAACTTCCAGC-3), p7702 (5GATGATATCGTGG-
GTGAGAACATTT-3) and p7702 (5GATGATATCGTGGGT-
GAGAACATTT-3). The primers for Z allele were p9966
(5ATAAGGCTGTGCTGACCATCGTC-3) and p10063 (5TAT-
TCCGACACGACTGGTAGCAG-3).
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RESULTS
Five of the 12 children studied were Z homozygotes (ZZ) whereas
two of the children had the S allele together with another allele which
was not Z (*S). Table 1 shows the patients age at the time of blood
collection and the indication used for deciding for subsequent analysis.
Three of the patients presented neonatal cholestasis as an initial
manifestation of chronic hepatopathy.
Table 2 shows the serum levels of ALT, AP, γGT, A1AT as well
as the results of the molecular study and liver biopsy.
The five patients with the ZZ genotype had reduced serum A1AT
levels and the liver biopsy showed cirrhosis (one), neonatal hepatitis
(two), a paucity of interlobular bile ducts (one) and chronic hepatitis
(one). In this last case (FSP), eosinophil-appearing cytoplasmic
granules were seen in periportal hepatocytes following staining with
HE and posteriorly confirmed by PAS positivity and diastase
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Table 1  Ages of the patients at the time of DNA analysis and the  indications used in their selection
Patient AGE Indication for DNA analysis
MFS 9 y Chronic hepatic disease of no defined etiology;  A1AT
EKBA 3 m Neonatal cholestase;  A1AT
RHBP 5 y Neonatal cholestase; chronic hepatic disease of no defined etiology;  A1AT
JCI 1y Neonatal cholestase; Chronic hepatic disease of no defined etiology;  A1AT
FSP 3 y Chronic hepatic disease of no defined etiology; A1AT
DO 19 y Chronic hepatic disease of no defined etiology
FSB 13 y Neonatal cholestase; Chronic hepatic disease of no defined etiology
TA 11 y Chronic hepatic disease of no defined etiology
CABC 8 y Chronic hepatic disease of no defined etiology
DPC 11 y Chronic hepatic disease of no defined etiology
YCPM 8 m Chronic hepatic disease of no defined etiology
JRA 6 y Chronic hepatic disease of no defined etiology
Table 2   Hepatic enzyme activities (IU/L), serum A1AT levels (g/L), liver biopsy results and individuals genotype
Patient ALT(IU/L) AP(IU/L) γGT(IU/L) A1AT(g/L) Biopsy Genotype
MFS 159 886     66 Undetect. Cirrhosis # ZZ
EKBA   50 45    974  0,86  Neonatal hepatitis #  ZZ
RHBP 696 1212   639 1,20 Intrahepatic biliary hipoplasia #  ZZ
JCI 394  4285    817 0,46  Neonatal hepatitis ##  ZZ
FSP   139 2503 887    0,40** Chronic hepatitis with portal fibrosis # ZZ
DO 44 1345 174 4,80 Chronic hepatitis and cirrhosis *S
FSB 146 1944 325 2,00 Portal fibrosis and ductupenia *S
TA 29 429  24 3,10   Portal fibrosis NEG. SZ
CABC 340 - 84 2,40 Chronic hepatobiliary disease NEG. SZ
DPC   26 632 27 3,40 Hepatocellular degeneration NEG. SZ
YCPM   84 822 33 3,60 Chronic active hepatitis NEG. SZ
JRA 15 13 45 0,85 NEG. SZ
#   PAS positive globules/diastase resistant
## PAS positive globules/diastase resistant in second biopsy
**  A1AT levels determined by nephelometry. The other
levels were determined by radial immunodiffusion.
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resistance (Figure 1). The two patients with neonatal cholestasis
(EKBA and RHBP) underwent a liver biopsy when they were 10
weeks and 13 weeks old, respectively, and showed eosinophilic PAS-
positive, diastase-resistent globules.
Figures 2 and 3 show the results of the amplification and digestion
of the S and Z alleles, respectively.
DISCUSSION
Alpha-1-antitrypsin deficiency is one of the most common genetic
disorders that leads to hepatic disease in children and it is the most
common genetic disease requiring liver transplantation(17, 28). A1AT
deficiency affects 1 out of 1600-2000 neonates in North America and
Northern Europe(28, 31), but only 10-15% of the population with this
deficiency develop hepatic diseases(32, 33). According to a study
published by SVEGER in 1988(33), during the neonatal period 11% of
the patients with the PIZZ phenotype develop icteric hepatitis. In
this study, three patients diagnosed with an A1AT deficiency had
neonatal cholestasis and in two of these, before a definite diagnosis of
the deficiency was established, the cholestasis was considered
idiopathic. Five to 10 percent of the cases of idiopathic neonatal
hepatitis reported in the literature are caused by an A1AT deficiency(3).
In five patients with this deficiency studied, the serum levels of
A1AT were below the normal lower limit. However, this test did not
absolutely confirm the diagnosis of the disease. Since A1AT is a protein
of the acute inflammatory phase, its synthesis increases in inflammatory/
infectious conditions, neoplasia, pregnancy and during therapy using
estrogens and corticosteroids(16, 22). A reduction in the serum levels of
A1AT occurs in the respiratory anguish syndrome of neonates, in the
terminal phase of hepatic failure, in cystic fibrosis and in situations in
which there is great protein loss(15). The serum levels in SZ genotypes,
which could theorically result in liver diseases, are usually normal.
When neonatal cholestasis is present, it is fundamentally necessary
a differential diagnosis with extrahepatic biliary atresia. The clinical
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FIGURE 1  PAS-positive, diastase-resistant globules in periportal
hepatocytes. (PAS 400X)
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FIGURE 2  Ethidium bromide stained polyacrylamide gel showing
the profile of normal and mutant A1AT digested with
the the restriction enzyme (Xmnl). Lanes 1, 2,4 and 5-
S heterozygotes, lane 3-normal homozygote, M-marker
(X 174/Hind III)
FIGURE 3  Ethidium bromide stained polyacrylamide gel showing
the profile of normal and mutant A1AT digested with
the restriction enzyme (Taq I). Lanes 1 and 3- Z
heterozygotes, lane 2- Z homozygote,  lane 4- normal
homozygote,  M-marker (X 174/Hind III)
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history allows an adequate diagnoses in 83% of the cases(1) and it is
necessary specific investigations in order to improve the accuracy of
the diagnosis. Among these investigations, the liver biopsy is of major
importance. The histopathological alterations seen in the liver biopsy
of patients with A1AT deficiency may be the same as those observed
in idiopathic neonatal hepatitis or in cases of extrahepatic biliary
atresia(24). The presence of predominantly periportal, intrahepa-
tocystic globules that are strongly PAS positive after diastase digestion
is a helpful indication of A1AT deficiency(13, 18, 27). However, it is
difficult to identify these globules before the 12th week after birth(35).
In this study, patient EKBA had globules with the above characteristics
in liver tissue at the age of 10 weeks. No such globules were seen in
De Tommaso AMA, Rossi CL, Escanhoela CAF, Serra HG, Bertuzzo CS, Hessel G. Diagnóstico da deficiência de alfa-1-antitripsina por estudo
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RESUMO - Racional - A deficiência de alfa-1-antitripsina é uma doença genética transmitida de forma autossômica co-dominante. As
manifestações clínicas principais incluem acometimento pulmonar e hepático. Este último, apresenta-se como colestase neonatal, hepatite
crônica ou cirrose. O diagnóstico definitivo é realizado pela análise bioquímica da alfa-1-antitripsina ou pela análise molecular. Objetivo
- Investigar, em um grupo de 12 crianças com suspeita de deficiência de alfa-1-antitripsina, a presença efetiva da deficiência através da
análise de DNA, para um diagnóstico definitivo, bem como a associação entre os deficientes de alfa-1-antitripsina com as características
clínicas e laboratoriais encontradas. Casuística e Métodos - Foram investigados os alelos mutantes S e Z do gene da alfa-1-antitripsina
em 12 pacientes com idade variando de 3 meses a 19 anos, encaminhadas pelo ambulatório de Gastroenterologia Pediátrica da Univer-
sidade Estadual de Campinas, SP, por apresentarem dosagem sérica de alfa-1-antitripsina inferior ao normal e/ou doença hepática sem
etiologia definida. A análise de DNA foi realizada utilizando-se o método modificado de amplificação gênica pela reação em cadeia de
polimerase que cria sítios de restrição para as enzimas Xmnl (alelo S) e Taq l (alelo Z). Resultados - Dos 12 pacientes encaminhados, 7
apresentavam doença hepática crônica sem etiologia definida e os outros 5 traziam dosagens séricas baixas de alfa-1-antitripsina
acompanhadas do diagnóstico de colestase neonatal e/ou doença hepática crônica de etiologia desconhecida. Nesse grupo de 12 pacientes,
foram observados cinco pacientes homozigotos Z (ZZ) e dois traziam o alelo S acompanhado de um outro alelo, diferente do Z (*S).
Conclusão - Esses resultados mostram que a deficiência de A1AT é uma etiologia relativamente freqüente em crianças que apresentam
doença hepática crônica sem etiologia definida e/ou dosagem sérica baixa de A1AT (41,6%). A importância de um diagnóstico de certeza
para a deficiência é justificada não apenas para o seguimento clínico do paciente mas também, em termos de aconselhamento genético.
DESCRITORES  Deficiência de alfa-1-antitripsina. Diagnóstico molecular. Biopsia hepática.
patient JCI (13 weeks old). These results suggest that the presence of
globules should be investigated using special staining in hepatic
fragments obtained before the age of 12 weeks, although a negative
result does not eliminate the possibility of A1AT deficiency.
Biochemical analysis was not used in this study since DNA analysis,
which is more precise, was possible.
An A1AT deficiency is relatively frequent in children who have
hepatic disease of undefined etiology. This diagnosis is subestimated,
probably because imprecise diagnostic methods are used. Molecular
analysis provides a more precise diagnosis and may also be useful for
the genetic counseling of patients with hepatic disease of unknown
etiology.
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